Research ArticleNuclear Oncology
Advantage of a Residualizing Iodine Radiolabel for Radioimmunotherapy of Xenografts of Human Non-Small-Cell Carcinoma of the Lung
Rhona Stein, David M. Goldenberg, Suzanne R. Thorpe and M. Jules Mattes
Journal of Nuclear Medicine March 1997, 38 (3) 391-395;
Rhona Stein
David M. Goldenberg
Suzanne R. Thorpe


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Advantage of a Residualizing Iodine Radiolabel for Radioimmunotherapy of Xenografts of Human Non-Small-Cell Carcinoma of the Lung
Rhona Stein, David M. Goldenberg, Suzanne R. Thorpe, M. Jules Mattes
Journal of Nuclear Medicine Mar 1997, 38 (3) 391-395;
Jump to section
Related Articles
- No related articles found.
Cited By...
- A New Tri-Fab Bispecific Antibody for Pretargeting Trop-2-Expressing Epithelial Cancers
- Advantage of a Residualizing Iodine Radiolabel in the Therapy of a Colon Cancer Xenograft Targeted with an Anticarcinoembryonic Antigen Monoclonal Antibody
- Improved Iodine Radiolabels for Monoclonal Antibody Therapy
- Antibody Localization to B-Cell Lymphoma Xenografts in Immunodeficient Mice: Importance of Using Residualizing Radiolabels
- Metabolite Production in Patients with Lymphoma After Radiometal-Labeled Antibody Administration
- Radioimmunotherapy of a Human Lung Cancer Xenograft with Monoclonal Antibody RS7: Evaluation of 177Lu and Comparison of Its Efficacy with That of 90Y and Residualizing 131I